Simplify Life with Omnipod® 5!

Omnipod 5 with no adhesive and device Omnipod 5 with no adhesive and device
Pod shown without necessary adhesive. Screen for illustrative purposes only.

Why Omnipod 5?

  • The first and only tubeless, waterproof automated insulin delivery system compatible with leading sensor brands* 
  • Automatically adjusts insulin every five minutes1,2
  • Delivered more than 80% time in range with optimised settings3.
3. Retrospective RWE data on file. 2025. Results shown for users with optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, ≥5 bolus/day and an average Target Glucose of 110-115 mg/dL (6.1-6.4 mmol/L). Optimized settings: ISF x TDI ≤1500(83 mmol/L), I:C Ratio x TDI ≤350. RF-062025-00014

What is Omnipod?

Omnipod is a range of tubeless insulin delivery systems.

Each waterproof, wearable Pod continuously delivers personalised doses of insulin for up to three days (72 hours).

With no tubes to cause unwanted tangles, it’s time to discover the freedom of Omnipod.

woman playing tennis woman playing tennis



Meet our Omnipod® lineup

Pod with controller Pod with controller
Screen for illustrative purposes only.
Omnipod Dash with controller Omnipod Dash with controller
Screen for illustrative purposes only.

Omnipod® 5 Automated Insulin Delivery System

Experience the freedom of automated insulin delivery and improved time in range1,2  with compatibility across leading sensor brands.
 

Omnipod DASH® Insulin Management System

You’re in control with the Omnipod DASH® Personal Diabetes Manager. Discover discreet, precise insulin dosing and customisable programmes designed to fit around your lifestyle.
 

How can I find out more about Omnipod?

We are delighted to have Nordic InfuCare as our distributor in Sweden. Please contact Nordic InfuCare directly to learn how to get started on the Omnipod 5 or Omnipod DASH in Sweden.

Address: Nordic InfuCare AB, Box 14026, 16714 Bromma, Sverige 

Email: [email protected]

Phone: +46 (0)8 601 24 40

Website: https://www.diabetesinfucare.com/sv/omnipod5 

Here’s what our Podders have to say about Omnipod…

When I first put Omnipod on, I felt free. There were no tubes coming off me.

Lochlan
Podder® since 2023
Lochlan is a Sponsored Podder®

Omnipod has helped me gain confidence in so many areas of my life, it makes me feel like I have something in my corner helping me every day.

Temi
Podder® since 2021
Sponsored Podder®

Omnipod was a game-changer for me. It empowered me and gave me back so much of my independence.

Sophie
Podder® since 2023
Sponsored Podder®

* Automated mode requires a compatible sensor. Compatible sensors are sold and prescribed separately.

The Pod has an IP28 rating for up to 7.6 metres (25 feet) for 60 minutes. The Omnipod 5 Controller is not waterproof. Please see sensor manufacturer user guide for sensor waterproof rating .

1. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) in adults/adolescents as measured by CGM: ST = 64.7%, 3-mo Omnipod 5 = 73.9%, P<0.0001. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) in children as measured by CGM: ST = 52.5%, 3-mo Omnipod 5 = 68.0%, P<0.0001.

2. Sherr J. et al. Diabetes Care. 2022; 45:1907-1910. Single-arm multicenter clinical trial in 80 pre-school children (aged 2-5.9 yrs) with T1D. Study included a 14-daystandard therapy (ST) phase followed by a 3-month AID phase with Omnipod 5 system.. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 57.2% vs 68.1%, P<0.0001.

3. Retrospective RWE data on file. 2025. Results shown for users with optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, ≥5 bolus/day and an average Target Glucose of 110-115 mg/dL (6.1-6.4 mmol/L). Optimized settings: ISF x TDI ≤1500 (83 mmol/L), I:C Ratio x TDI ≤350. RF-062025-00014. 
Omnipod 5 Controller+ Pod+sensors_UK Omnipod 5 Controller+ Pod+sensors_UK
Screen is an example and for illustrative purposes only

The first and only tubeless automated insulin delivery system that works with the leading sensor brands*

Omnipod 5 is the first wearable, tubeless, hybrid closed loop insulin delivery system to integrate with the Dexcom G6 sensor and the FreeStyle Libre 2 Plus sensor**.

Omnipod 5 automatically adjusts insulin delivery every 5 minutes, helping to protect against highs and lows.1,2 It’s the​​ system that never sleeps.

What is Pod Therapy?

Pod Therapy is simple, tubeless, discreet insulin pump therapy for people living with type 1 diabetes, ages 2 and older.

Each wearable Pod continuously delivers personalised doses of insulin for up to three days (72 hours), controlled wirelessly by you, wherever you are.

With no multiple daily injections and no tubes, Pod Therapy is insulin pump therapy, simplified. Only found with Omnipod®.

Father and daughter doing homework together in the kitchen Father and daughter doing homework together in the kitchen
Omnipod 5 with Pod and no adhesive shown on a transparent background Omnipod 5 with Pod and no adhesive shown on a transparent background
Pod shown without necessary adhesive

Omnipod 5 Automated Insulin Delivery System

Now available with a choice of glucose sensor! Omnipod 5 automatically adjusts your insulin every five minutes, helping to stay in range throughout the day and night.

Omnipod DASH with Pod and without adhesive on a transparent background Omnipod DASH with Pod and without adhesive on a transparent background
Pod shown without necessary adhesive

Omnipod DASH® Insulin Management System

​​​You’re in control with the Omnipod DASH® Personal Diabetes Manager. Discover discreet, precise insulin dosing and customisable programmes designed to fit around your lifestyle.

Here’s what our Podders have to say about Omnipod…

Omnipod 5 has allowed me to get a good night sleep. That's the first time I can say that in a long time.

Alvin
Podder since 2017

It helps me feel like a normal kid, just with a little bit of help.

Romey T.
Sponsored Podder®

I don’t have to spend as much time thinking about diabetes.

Clare F.
Podder® since 2013

How can I find out more about the Omnipod?

We are delighted to have NordicInfu Care as our distributor in Sweden. Please contact NordicInfu Care directly to learn how to get started on the Omnipod 5 or Omnipod DASH.

Adress: NordicInfu Care AB , 
Box 14026, 16714 Bromma, Sverige

E-post: [email protected]

Telefon: +46 (0)8 601 24 40

Women having lunch at a cafe Women having lunch at a cafe
* Requires Dexcom G6 or FreeStyle Libre 2 Plus sensor. Bolus for meals and corrections are still needed.
**A separate prescription is required for the sensor. The Dexcom G6 and FreeStyle Libre 2 Plus sensors are sold separately.
† The Pod has an IP28 rating for up to 7.6 metres (25 feet) for 60 minutes. The Omnipod 5 Controller is not waterproof. Please see sensor manufacturer user guide for sensor waterproof rating.
‡ Fingerpricks required for diabetes treatment decisions if symptoms or expectations do not match readings.
1. Study in 240 people with T1D aged 6 - 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose in adults/adolescents and children, standard therapy vs. 3-month Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%. Median time with low blood glucose in adults/adolescents and children, standard therapy vs. 3-mo Omnipod 5: 2.0% vs. 1.1%; 1.4% vs. 1.5%. Brown et al. Diabetes Care (2021)
2. Study in 80 people with T1D aged 2 - 5.9 yrs involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose (>180mg/dL) from CGM in standard therapy vs Omnipod 5 = 39.4% vs. 29.5%. Average time with low blood glucose (<70mg/dL) from CGM in standard therapy vs Omnipod 5 = 3.41% vs. 2.13%. Sherr JL, et al. Diabetes Care (2022).